THABOR THERAPEUTICS

Will attend BioPharm America 2022

Develops innovative treatments for human mucosal inflammatory diseases by preventing inflammation and fibrosis, as well as restoring epithelial integrity

Pipetting Samples
 

SCIENCE

A new target for mucosal inflammatory diseases

user.png

Thabor therapeutics is a biotechnology company focused on treating human mucosal inflammatory diseases by inhibiting a new target that could be implied in the early inflammatory process and the recruitment of innate immunity cells. The company aims to develop first-in-class drugs targeting specifically a new class of proteins involved in the resolution of the inflammation.

 
Science Student
 

MANAGEMENT TEAM

The company is managed by a highly-experienced and complementary team.

Photo JM.jpg

JÉRÉMIE MARIAU

CEO

After a graduation from a life science engineering school degree and a MSc in Human genetics and cellular biology, spent 15 years in the biotech/biopharma industry. Previously CEO of ILTOO Pharma, and COO of Alfact Innovation.

1619042929494_edited.jpg

CLEMENT BERTHOLET

VP Corporate Development

After a MSc in Molecular Biology from Ecole Normale Supérieure de Cachan and a specialisation in epigenetics, spent 6 years as a Corps des Mines chief engineer in corporate finance and restructuring for the French Ministry of Economy and Finance.

Stéphanie_edited_edited.jpg

STEPHANIE BEQ, PHD

R&D Director

After a PhD in immunological studies in the laboratory of Françoise Barre-Sinoussi (Nobel Price in 2008), spent 15 years of research and drug discovery & development in immunology. Previously Senior Director at HiFiBiO, Alexion, Stallergenes, and Cytheris. 
24 publications & 2 Patents

 

SCIENTIFIC TEAM

Our scientific team consists of 3 scientific founders used to entrepreunarial experiences, who conducted academic research (at INSERM and AP-HP) over the past decade to identify the new target.

CHEVET_Eric.jpg

ERIC CHEVET, PHD

Co-founder

  • Research director at INSERM, head INSERM U1242, 

  • Expert in endoplasmic reticulum biology,

  • 193 publications (Pubmed),

  • H-index 60 (Google Scholar),

  • 9 patents, Cofounder of Cell Stress Discoveries Ltd.

  • Co-editor in chief Traffic

thumbnail_IMG_0368.jpg

ERIC OGIER-DENIS, PHD

Co-founder

  • Research director at INSERM 

  • Expert in pathophysiology of IBD,

  • Partner Labex Inflamex Paris

  • 82 publications (Pubmed),

  • H-index 45 (Google Scholar),

  • 14 patents, Cofounder Inception IBD (Versant Ventures, Celgene) 

Xavier Treton_edited.jpg

XAVIER TRETON, MD-PHD

Co-founder

  • Professor of Gastroenterology at Beaujon Hospital, APHP, Paris,

  • Expert in IBD, clinical and translational research (Biomarkers)

  • 84 publications (Pubmed)

  • H-index 27 (Google Scholar)

  • 11 patents, Cofounder Inception IBD (Versant Ventures, Celgene)

  • Head of GI tissueBank, Beaujon Hospital

 

CONTACT

Merci pour votre envoi !